US FDA News 4/4

top of page

bluebird bio's $2.8 million gene therapy Zynteglo received FDA nod for beta-thalassemia

bluebird bio's $2.8 million gene therapy Zynteglo received FDA nod for beta-thalassemia

bluebird bio's $2.8 million gene therapy Zynteglo received FDA nod for beta-thalassemia

ipharmaservices

Aug 19, 2022

BMS' Breyanzi was approved for relapsed or refractory LBCL | News | FDA | iPharmacenter

BMS' Breyanzi was approved for relapsed or refractory LBCL | News | FDA | iPharmacenter

BMS' Breyanzi was approved for relapsed or refractory LBCL | News | FDA | iPharmacenter

ipharmaservices

Jun 25, 2022

FDA approved two Opdivo based regimens as a 1L treatment for ESCC | FDA News | iPharmaCenter

FDA approved two Opdivo based regimens as a 1L treatment for ESCC | FDA News | iPharmaCenter

FDA approved two Opdivo based regimens as a 1L treatment for ESCC | FDA News | iPharmaCenter

ipharmaservices

May 30, 2022

FDA approved Kymriah for follicular lymphoma | Novartis | News | Cancer | | Updates | iPharmaCenter

FDA approved Kymriah for follicular lymphoma | Novartis | News | Cancer | | Updates | iPharmaCenter

FDA approved Kymriah for follicular lymphoma | Novartis | News | Cancer | | Updates | iPharmaCenter

ipharmaservices

May 29, 2022

FDA gave the nod to Pfizer's Paxlovid | Pfizer to supply 2.5 million doses of Paxlovid to the UK

FDA gave the nod to Pfizer's Paxlovid | Pfizer to supply 2.5 million doses of Paxlovid to the UK

FDA gave the nod to Pfizer's Paxlovid | Pfizer to supply 2.5 million doses of Paxlovid to the UK

ipharmaservices

Dec 23, 2021

~$10 bn acquisition paying off for Novartis as FDA approved Novartis' Leqvio

~$10 bn acquisition paying off for Novartis as FDA approved Novartis' Leqvio

~$10 bn acquisition paying off for Novartis as FDA approved Novartis' Leqvio

ipharmaservices

Dec 23, 2021

Gilead’s Trodelvy approved for triple-negative breast cancer in US

Gilead’s Trodelvy approved for triple-negative breast cancer in US

Gilead’s Trodelvy approved for triple-negative breast cancer in US

ipharmaservices

Apr 9, 2021

FDA to review the accelerated approvals of Keytruda, Opdivo, and Tecentriq

FDA to review the accelerated approvals of Keytruda, Opdivo, and Tecentriq

FDA to review the accelerated approvals of Keytruda, Opdivo, and Tecentriq

ipharmaservices

Mar 13, 2021

FDA approved Roche’s Gavreto for RET fusion-positive NSCLC

FDA approved Roche’s Gavreto for RET fusion-positive NSCLC

FDA approved Roche’s Gavreto for RET fusion-positive NSCLC

ipharmaservices

Sep 7, 2020

bottom of page